The investigators are hypothesizing that decreasing estrogen levels will cause serum DKK1 to peak, then decrease gradually as estrogens reach a new lower, but steady level. The investigators also believe that the peak in DKK1 will initiated a wave of stem cell diversion from the osteoblastogenic pathway to the adipogenic pathway.
The investigators will conduct a longitudinal cohort study of post menopausal women with hormone-responsive breast cancer that will be treated AIs. The study will observe anthromorphic and serum marker changes during the first year of their treatment.
Post Menopausal Breast cancer patients with planned treatment of aromatase inhibitors. 18 years or older
Exclusion Criteria:
BMI >30 or <18 Osteoporosis as defined by protocol. Subjects currently on bisphosphonate therapy. History of primary or secondary hyperparathyroidism History of Hypo-or Hyperthyroidism History of Vitamin D levels below LLN History of creatinine clearance below the EGFR History ofLiver function tests above 1.5 times ULN including LDH, SGOT, SGPT, Alkaline phosphatase, and Bilirubin History of documented cirrhosis of the liver History of chronic heparin use History of chronic glucocorticoid therapy
